{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:29:51Z","timestamp":1786969791604,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejca.2024.114191","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T02:59:40Z","timestamp":1719197980000},"page":"114191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor"],"prefix":"10.1016","volume":"207","author":[{"given":"Anne-Claire","family":"Toublanc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Faure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Verdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Rabeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Houard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Veillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bardel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Vergnenegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Zysman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10212","key":"10.1016\/j.ejca.2024.114191_bib1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ejca.2024.114191_bib2","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ejca.2024.114191_bib3","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114191_bib4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol mai"},{"issue":"2","key":"10.1016\/j.ejca.2024.114191_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade. Longo DL, \u00e9diteur","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114191_bib6","doi-asserted-by":"crossref","unstructured":"Naqash A.R., Moey M.Y.Y., Cherie Tan X.W., Laharwal M., Hill V., Moka N., et al. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute\u2014Cancer Therapy Evaluation Program. JCO. 4 juin 2022;JCO.22.00369.","DOI":"10.1200\/JCO.22.00369"},{"issue":"12","key":"10.1016\/j.ejca.2024.114191_bib7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114191_bib8","unstructured":"Data collections - WHO [Internet]. [cited August the 4th 2023]. Website: \u3008https:\/\/www.who.int\/data\/collections\u3009."},{"issue":"1","key":"10.1016\/j.ejca.2024.114191_bib9","first-page":"137","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"JACC: CardioOncology"},{"issue":"41","key":"10.1016\/j.ejca.2024.114191_bib10","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.ejca.2024.114191_bib11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","article-title":"Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance","volume":"44","author":"Mascolo","year":"2021","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.ejca.2024.114191_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ejca.2024.114191_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.lungcan.2015.01.006","article-title":"Cardiovascular comorbidities and survival of lung cancer patients: medicare data based analysis","volume":"88","author":"Kravchenko","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2024.114191_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/918368","article-title":"Adult current smoking: differences in definitions and prevalence estimates\u2014NHIS and NSDUH, 2008","volume":"2012","author":"Ryan","year":"2012","journal-title":"J Environ Public Health"},{"issue":"2","key":"10.1016\/j.ejca.2024.114191_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.ejca.2024.114191_bib16","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.ejca.2024.114191_bib17","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114191_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.878211","article-title":"A prospective study to detect immune checkpoint inhibitors associated with myocarditis among patients treated for lung cancer","volume":"9","author":"Faubry","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"16","key":"10.1016\/j.ejca.2024.114191_bib19","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114191_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor\u2013associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.ejca.2024.114191_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejca.2024.114191_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.114191_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","article-title":"Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms","volume":"33","author":"Champion","year":"2020","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114191_bib24","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1634\/theoncologist.2019-0040","article-title":"Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: the memorial sloan kettering cancer center experience","volume":"24","author":"Lee Chuy","year":"2019","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.ejca.2024.114191_bib25","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jacc.2015.02.044","article-title":"Implications of introducing high-sensitivity cardiac troponin T Into clinical practice: data from the SWEDEHEART Registry","volume":"65","author":"Melki","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114191_bib26","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1373\/clinchem.2016.256305","article-title":"Incidence of undetectable, measurable, and increased cardiac troponin i concentrations above the 99th percentile using a high-sensitivity vs a contemporary assay in patients presenting to the emergency department","volume":"62","author":"Love","year":"2016","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.ejca.2024.114191_bib27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.ejca.2024.114191_bib28","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1161\/CIRCULATIONAHA.121.055816","article-title":"Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ejca.2024.114191_bib29","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.ejca.2024.114191_bib30","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1200\/JCO.21.01806","article-title":"Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN Renal 101 Trial","volume":"40","author":"Rini","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114191_bib31","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1634\/theoncologist.2019-0040","article-title":"Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience","volume":"24","author":"Lee Chuy","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114191_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","author":"Laenens","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114191_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00392-020-01648-3","article-title":"Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis","volume":"110","author":"Peleg Hasson","year":"2021","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114191_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002553","article-title":"Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Puzanov","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.114191_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2217\/fca-2022-0120","article-title":"Immune checkpoint inhibitor-associated myocarditis: from pathophysiology to rechallenge of therapy - a narrative review","volume":"19","author":"Tedeschi","year":"2023","journal-title":"Future Cardiol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114191_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002553","article-title":"Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Puzanov","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2024.114191_bib37","first-page":"476","article-title":"Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event","volume":"36","author":"Cautela","year":"2020","journal-title":"Can J Cardiol"},{"issue":"10","key":"10.1016\/j.ejca.2024.114191_bib38","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1513\/AnnalsATS.201706-442ED","article-title":"Comorbidity profiles of patients with lung cancer: a new approach to risk stratification?","volume":"14","author":"Sigel","year":"2017","journal-title":"Ann ATS"},{"issue":"4","key":"10.1016\/j.ejca.2024.114191_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.ejca.2024.114191_bib40","article-title":"Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors","author":"Bukhari","year":"2022","journal-title":"Cell Rep Med"},{"issue":"2","key":"10.1016\/j.ejca.2024.114191_bib41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:21:45Z","timestamp":1786969305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":41,"alternative-id":["S0959804924008475"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114191","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114191"}}